In an hour-long meeting at Eli Lilly and Company’s headquarters in Indianapolis on April 15, the pharmaceutical company’s top ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

Pfizer has been paying dividends for 35 years and raising them for 14 years. Read more to see whether PFE stock is a buy.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

It also offers a high dividend yield of about 8%, which could help keep the stock price from falling much further. The BofA analyst notes that the long-term growth outlook is weaker than average due ...

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S.

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

We recently published a list of the 10 Safe Dividend Stocks with Yields Above 5%. In this article, we are going to take a ...

BofA lowered the firm’s price target on Pfizer (PFE) to $26 from $29 and keeps a Neutral rating on the shares. For Q1, the firm’s total revenue ...

Pfizer's strong R&D pipeline, 7.5%+ dividend yield, & undervalued PE ratio make PFE stock a compelling investment opportunity ...

Pfizer has encountered many setbacks in its quest to launch a medicine that could rival Wegovy and Zepbound. One of its ...